Patent ID: 8591901

Claim:
A method of inhibiting TGFβ1, TGFβ2 or TGFβ3 signaling, comprising the step of contacting TGFβ1, TGFβ2 and TGFβ3 in vivo with an isolated specific binding member that binds to TGFβ1, TGFβ2 and TGFβ3, said binding member comprising an antigen-binding domain of an antibody, wherein the heavy chain of said antibody comprises: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 4, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 5; and wherein the light chain of said antibody comprises: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 10.